Clinical trials: Tauopathies
Disc Disease, Instabilities Lumbar
Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment
Analyzing the impact of surgery and adverse events (AEs) on patients' well-being is of paramount importance as it provides essential information for benefit-risk assessment.
- Conditions
- Disc Disease, Instabilities Lumbar, Brain Tumor, Aneurysm
- Trial name
- NCT06352710
- Testing
- OP-Tracker App
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- Cantonal Hospital of St. Gallen
Alzheimer Disease, ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder)
Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003
In the perspective to better evaluate the efficacy of new treatment strategies for Alzheimer disease (AD), it appears important to develop experimental paradigms to precisely measure cognitive endpoints/biomarkers that may be…
- Trial name
- PharmacogWP3 (NCT02899403)
- Testing
- Rapid Visual Information Processing (RVIP) test
- Where
- France
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer Disease
Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease
This is a randomized sham control study to evaluate how repetitive Transcranial Magnetic Stimulation (rTMS), interactive cognitive training, or the combination of rTMS and cognitive training reduce the cognitive decline of…
- Trial name
- TMS_AD (NCT04440891)
- Testing
- TMS stimulation with X-Torp task, TMS-Stimulation with MindMotion Go
- Where
- United States
- Sponsor
- Ali Rezai
Alzheimer's Disease
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic [PK] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of…
- Trial name
- NCT01702480
- Testing
- GSK2981710
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00667810
- Testing
- bapineuzumab
- Where
- 346 sites in United States, Argentina and 24 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety Study of CTS21166 to Treat Alzheimer Disease
This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
- Trial name
- CTS (NCT00621010)
- Testing
- CTS21166 (ZPQ-21166)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CoMentis
Progressive Supranuclear Palsy
The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)
Progressive Supranuclear Palsy (PSP) is a rapidly progressive neurodegenerative disease characterized by falls and oculomotor disturbances.
- Trial name
- NCT04691635
- Testing
- evaluation of movements with sensors
- Where
- 3 sites in Italy
- Volunteers
- 165 people
- Sponsor
- University of Salerno
Alzheimer's Disease and Related Dementias
OPTIMAL in NH Residents With Dementia
The purpose of this study is to develop and refine OPTIMAL and evaluate its feasibility, fidelity, and usefulness. The OPTIMAL is designed to teach staff to effectively engage residents in eating using individualized…
- Trial name
- NCT05255068
- Testing
- OPTIMAL
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- University of Iowa
Alzheimer Disease
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.
- Trial name
- NCT04251182
- Testing
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer's Disease and Related Dementias, Quality of Life
Supporting Our Caregivers In ADRD Learning (SOCIAL)
Building on limitations of prior research, the investigators developed the Mindful and Self-Compassionate Care Program (MASC) to help caregivers of persons with Alzheimer Disease and Related Dementias (ADRD) manage stress…
- Conditions
- Alzheimer's Disease and Related Dementias, Quality of Life, Caregiver Stress
- Trial name
- SOCIAL (NCT06276023)
- Testing
- Mindful and Self-Compassionate Care Program (MASC), Health Education Program (HEP)
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Progressive Supranuclear Palsy
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT02985879
- Testing
- ABBV-8E12
- Where
- 66 sites in United States, Australia and 6 more
- Volunteers
- 378 people
- Sponsor
- AbbVie
Alzheimer Disease
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.
- Trial name
- TB006SAD (NCT04920786)
- Testing
- TB006
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- TrueBinding, Inc.
Dementia, Mixed, Dementia Mild
An Innovative Supportive Care Model for Dementia and Traumatic Brain Injury
There are an increasing number of people in the U.S. with Alzheimer's disease and other dementias. Traumatic brain injuries (TBIs) are also common among both civilians and military personnel, and TBIs increase a person's risk for…
- Conditions
- Dementia, Mixed, Dementia Mild, Dementia Moderate, Traumatic Brain Injury
- Trial name
- NCT04495686
- Testing
- Telehealth-delivered Care Coordination Program
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- University of Virginia
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842673
- Testing
- ST101
- Where
- 18 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Sonexa Therapeutics, Inc.
Alzheimer's Disease, Cardiovascular Risk Factors
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Three quarters of patients with Alzheimer's disease have at least one vascular risk factor (VRF). Vascular brain lesions are present in most Alzheimer's patients (especially older ones).
- Trial name
- COVARAD (NCT01423396)
- Testing
- optimal care of VRF, standard care
- Where
- 21 sites in France
- Volunteers
- 304 people
- Sponsor
- University Hospital, Lille
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
The primary objective of this feasibility study is to evaluate the safety of DBS-f in patients with mild Alzheimer's disease by assessing all device and/or therapy related adverse events.
- Trial name
- ADvance (NCT01608061)
- Testing
- DBS-f on, DBS-f off
- Where
- 7 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Functional Neuromodulation Ltd
Alzheimer Disease
Effect of Music Therapy on Anxiety of Caregivers of Alzheimer's Disease Patients
This clinical trial evaluates the impact of music interventions on caregivers of patients with memory disorders, Alzheimer's disease, dementia and related disorders.
- Trial name
- NCT05317910
- Testing
- MUSIC CARE
- Where
- France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Association de Musicothérapie Applications et Recherches Cliniques